Tricida gains on long-term Phase III data for metabolic acidosis therapy

Shares of Tricida jumped $13.73 (57%) to $37.80 on Thursday after veverimer (TRC101) significantly reduced a composite of all-cause mortality and/or progression of chronic kidney disease in the Phase III TRCA-301E extension trial to treat metabolic acidosis in

Read the full 388 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE